In this issue, Overacre-Delgoffe et al. show that interferon gamma production by a subset of regulatory T cells in the tumor microenvironment triggers Treg instability locally and restores anti-tumor immunity.
Regulatory T cells (Tregs) play a central role in the maintenance of self tolerance and immune homeostasis (Plitas and Rudensky, 2016) . Although Tregs are essential in limiting autoimmunity and in finetuning inflammation after infection, they also limit anti-tumor immunity and allow tumor progression (Tanaka and Sakaguchi, 2017) . Indeed, the number of Tregs present in the tumor and, in particular, a decreased ratio of effector CD8 + T cells to Tregs correlates with poor prognosis in multiple cancers (Li et al., 2010) . However, the exact molecular basis of Treg function, Tregs' role in tumor tissue, and, in particular, development of means to deplete the appropriate Treg subsets while limiting autoimmunity remain elusive.
In previous work, Vignali and colleagues found that neuropilin-1 (Nrp1) is expressed by the majority of intratumoral Tregs and is key to their suppressive function within the tumor given that they become functionally unstable and lose their suppressive ability when Nrp1 is inactivated (Delgoffe et al., 2013) . As a result, mice with deletion of Nrp1 in Tregs are resistant to B16 melanoma tumor implantation and do not display any autoimmune or inflammatory disease.
Treg functional instability and lineage plasticity have captured the attention of the Treg field and have generated some degree of controversy (Hori, 2014; Overacre and Vignali, 2016) . Although previous work has clearly shown the importance of Nrp1 in Treg fragility, the impact and relevance of this finding in human cancer has remained unclear.
To begin to answer this question, Overacre-Delgoffe et al. (2017 [this issue of Cell]) asked whether NRP1 is expressed in the Tregs of patients with melanoma and head and neck squamous cell carcinoma (HNSCC). While very few Tregs in healthy donors express NRP1, a significant but variable fraction of intratumoral Tregs in patients with melanoma (3%-90%) or HNSCC (35%-90%) are NRP1+. This variation in frequency of NRP1+ Tregs raises the question of whether NRP1+ expression in only a subset of Tregs within the tumor microenvironment is relevant for tumor growth. To address this question, the authors set up a clever system by which they can test the impact of Nrp1 loss in a subset of Tregs on the function of the remaining wild-type (WT) counterparts and on the tumor microenvironment (Figure 1 anti-tumor immunity, and promoting tumor growth. This observation provides insight into possible mechanisms underlying Treg fragility within an inflamed tumor microenvironment and shows that targeting a subset of Tregs may be sufficient to block their suppressive function. In order to test the potential relevance of these observations in a clinical setting, the authors evaluated the strategy in a preclinical fibrosarcoma mouse model and found that IFNg receptor inactivation in Tregs abrogates the effect of PD-1 blockade therapy. This observation suggests that IFNg-induced T cell fragility is required for effective PD-1 targeted immunotherapy. Their findings underscore the impact of Treg fragility on tumor progression and highlight the fact that one of the mechanisms by which local inflammation induced by checkpoint blockade (anti-PD-1) contributes to tumor protection is via Treg fragility. These findings invite the possibility of manipulating intratumoral suppressive T cell function while maintaining peripheral tolerance by targeting NRP1, in the context of checkpoint blockade.
Multiple approaches are being used to try to reduce intratumoral Tregs. Sakaguchi and colleagues have reported that CCR4 is expressed in Tregs' infiltrating tumors. Multiple clinical trials are being conducted with anti-CCR4, mogamulizumab (Sugiyama et al., 2013 ) (ClinicalTrials.gov identifiers NCT02946671 and NCT0161114). Other targets that are being explored in early phase clinical trials are members of the TNF receptor super-family OX40 and GITR (Sanmamed et al., 2015) . Our group has recently shown that in a phase 1 clinical trial evaluating the GITR TRX518 agonist antibody, TRX518 preferentially targets intratumor Tregs. Other means to target Tregs include small molecules that target PI3 kinase delta signaling, chemotherapy that preferentially depletes Tregs, and the use of checkpoint immune blockade itself, which has been shown to deplete Tregs in pre-clinical models (Simpson et al., 2013 
